

3
346

FORM 27

THE PATENT ACT, 1970
(39 OF 1970)
&
THE PATENTS RULES, 2003
(As Amended)

**STATEMENT REGARDING THE WORKING OF THE PATENTED
INVENTION ON COMMERCIAL SCALE IN INDIA**

[See section 146(2) and rule 131(1)]

In the matter of Patent No.221674 of 15.04.2004.

I/We, Novartis AG, a corporation organized and existing under the laws of Switzerland of Lichtstrasse 35, CH-4056 Basel, Switzerland.

The patentee(s) or licensee(s) under Patent No.221674 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2010.

(i) The patented invention:

{ } Worked { } Not-worked [Tick () mark the relevant box].

~~(a) if not worked reasons for not working and steps being taken for working of the invention:~~

(b) if worked: quantum and value of the patented product:

(i) manufactured in India:

(ii) imported from other countries (give country wise details):

Product: Myfortic
Imported from Switzerland and Europe
Marketed by : Novartis India Limited
Quantum: No. of Units 22280
Value: Rupees 120239656

54,000/unit

(ii) The licences and sub-licences granted during the year:

(iii) State whether public requirement has been met partly/adequately/to the fullest extent at reasonable price:

The facts and matters stated above are true to the best of my/our knowledge, information and belief.

Dated this the 18th day of March, 2011

Neel
Of Anand and Anand, Advocates
Agent for the Patentee

To
The Controller of Patents
The Patent Office, Chennai

"THIS DOCUMENT IS SUPPLIED
UNDER THE RIGHT TO INFORMATION ACT"

347

No Fee

**STATEMENT REGARDING THE WORKING OF THE PATENTED
INVENTION ON COMMERCIAL SCALE IN INDIA**
[See section 146(2) and rule 131(1)] (As Amended)]

In the matter of Patent No. **221674 (772/CHENP/2004)** of 16th October, 2002.

We, **Novartis AG**, a corporation organized and existing under the laws of Switzerland, of Lichstrasse 35, CH-4056 Basel Switzerland.

The patentee(s) or licensee(s) under Patent No. **221674** hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year **2012**.

(i) The patented invention:

{} Worked ~~{} Not worked~~ [Tick () mark the relevant box].

(a) If not worked : reasons for not working and steps being taken for working of the invention:

(b) If worked : quantum and value (in Rupees), of the Patented Product:

(i) ~~manufactured in India~~

(ii) Imported from other countries. (give country wise details)

Product(s)	Quantum (No. of Units)	Value (Rupees)	Imported from:	Marketed by:
Myfortic	464,234	182,623,470	Switzerland	Novartis India Limited Sandoz House, 8th floor Shivsagar Estate Dr. Annie Besant Road Worli, Mumbai 400 018
			Europe	

(ii) The licenses and sub-licensees granted during the year: **None**

(iii) State whether public requirement has been met partly/adequately/to the fullest extent at reasonable price: **"YES."**

The facts and matters stated above are true to the best of my/our knowledge, information and belief.

Dated this 26th day of March, 2013

Neeti
Neeti Wilson
Of Anand and Anand, Advocates
Agent for the Patentee

To
The Controller of Patents
The Patent Office, Chennai

sw
TRUE COPY

FORM 27
THE PATENT ACT, 1970
(39 OF 1970)
&
THE PATENTS RULES, 2003

No Fee

STATEMENT REGARDING THE WORKING OF THE PATENTED
INVENTION ON COMMERCIAL SCALE IN INDIA
[See section 146(2) and rule 131(i)] (As Amended)]

In the matter of Patent No. 221674 (772/CHENP/2004) of 16th October, 2002.

We, Novartis AG, a corporation organized and existing under the laws of Switzerland, of 35, Lichtstrasse, CH-4056 Basel Switzerland.

The patentee(s) or licensee(s) under Patent No. 221674 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2013.

- (i) The patented invention:
 Worked Not-worked [Tick (✓) mark the relevant box].
 (i) - If not worked - reasons for not working and steps being taken for working of the invention:
 (b) If worked : quantum and value (in Rupees), of the Patented Product:
 (i) manufactured in India
 (ii) imported from other countries, (give country wise details):

S.No.	Product(s)	Quantum (number of units)	Value (Rs.)
1.	Myfortic 180MG T10 360MG T10	88,656 492,079	17,738,657 195,214,283

Imported from Switzerland and Europe
Marketed by : Novartis India Limited

(ii) The licenses and sub-licensees granted during the year;

(iii) State whether public requirement has been met partly/adequately/to the fullest extent at reasonable price: Yes

The facts and matters stated above are true to the best of my/our knowledge, information and belief.

Dated this 28th day of March 2014

Rakhee
Rakhee Sharma
Of Anand and Anand, Advocates
Agent for the Patentee

To
The Controller of Patents,
The Patent Office,
Chennai

349

Form-27

The Patents Act, 1970
(39 of 1970)

**STATEMENT REGARDING THE WORKING OF THE PATENTED INVENTION
ON COMMERCIAL SCALE IN INDIA**

[See Section 146(2) and rule 131(1)]

In the matter of Patent No. 222346
of 02 June 2000

I/We, NOVARTIS AG, BASEL, SWITZERLAND

the patentee(s) under Patent No. 222346 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2010.

- (i) The patented invention:
 worked not worked (tick relevant box [✓])

If not worked: reason for not working and steps being taken for working of the Invention : Nothing in particular

If worked: quantum and value (in Rupees), of the patented product:
Not applicable

Manufactured in India: No

Imported from other countries. (give country-wise details): Nil

- (ii) the licences and sub-licences granted during the year : No
- (iii) state whether public requirement has been met partly / adequately / to the fullest extent at reasonable price: Not applicable

The facts and matters stated above are true to the best of our knowledge, information and belief.

Dated this 25 day of March 2011

NOVARTIS AG, BASEL, SWITZERLAND
By his/their Agent and Attorney


R.R. NAIR

REG. No: IN/PA-121
of De Penning & De Penning

The Controller of Patents
The Patent Office at
Chennai

"THIS DOCUMENT IS SUPPLIED
UNDER THE RIGHT TO INFORMATION ACT"

TRUL COPY

FORM 27
THE PATENT ACT, 1970
(39 OF 1970)
 &
THE PATENTS RULES, 2003

350

No Fee

**STATEMENT REGARDING THE WORKING OF THE PATENTED
 INVENTION ON COMMERCIAL SCALE IN INDIA**
 [See section 146(2) and rule 131(1)] (As Amended)]

In the matter of Patent No. **222346 (IN/PCT/2001/1673/CHE)** of 02nd June, 2000

We, **Novartis AG**, a corporation organized and existing under the laws of Switzerland, of **Lichstrasse 35, CH-4056 Basel** Switzerland.

The patentee(s) or licensee(s) under Patent No. **222346** hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year **2012**.

(i) The patented invention:

{} Worked {} Not worked [Tick () mark the relevant box].

(a) If not worked : reasons for not working and steps being taken for working of the invention:

(b) If worked : quantum and value (in Rupees), of the Patented Product:

- (i) manufactured in India
- (ii) Imported from other countries. (give country wise details)

Product(s)	Quantum (No. of Units)	Value (Rupees)	Imported from	Marketed by:
Onbrez	53144	33,649,046	Switzerland	Novartis Healthcare Private Limited Sandoz House, 8th floor Shivsagar Estate Dr. Annie Besant Road . Worli, Mumbai 400 018 Until 2012 Lupin Ltd from July 2012
			Europe	

(ii) The licenses and sub-licensees granted during the year: **None**

(iii) State whether public requirement has been met partly/adequately/to the fullest extent at reasonable price: **"YES."**

The facts and matters stated above are true to the best of my/our knowledge, information and belief.

Dated this **26th** day of **March, 2013**

Neel Wilson
Neel Wilson
Of Anand and Anand, Advocates
Agent for the Patentee

To
 The Controller of Patents
 The Patent Office, Chennai

an
PC

FORM 27
THE PATENT ACT, 1970
(39 OF 1970)
 &
THE PATENTS RULES, 2003

No Fee

**STATEMENT REGARDING THE WORKING OF THE PATENTED
 INVENTION ON COMMERCIAL SCALE IN INDIA**
[See section 146(2) and rule 131(1)] (As Amended)]

In the matter of Patent No. 222346 (IN/PCT/2001/1673/CHE) of 02nd June, 2000.

We, Novartis AG, a corporation organized and existing under the laws of Switzerland, of 35, Lichtstrasse, CH-4056 Basel Switzerland.

The patentee(s) or licensee(s) under Patent No. 222346 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2013.

(i) The patented invention:
 {} Worked Not-worked [Tick () mark the relevant box].

~~(r) If not worked - reasons for not working and steps being taken for working of the invention:~~

(b) If worked : quantum and value (in Rupees), of the Patented Product:

(i) manufactured in India

(ii) imported from other countries. (give country wise details):

S.No.	Product(s)	Quantum (number of units)	Value (Rs.)
1.	Onbrez		
	0.300mg 3x10	32,551	19,646,754
	0.150mg (3x10)	21,314	12,841,024

Imported from Switzerland and Europe

Marketed by : Lupin Ltd.

(ii) The licenses and sub-licensees granted during the year;

(iii) State whether public requirement has been met partly/adequately/to the fullest extent at reasonable price: Yes

The facts and matters stated above are true to the best of my/our knowledge, information and belief.

Dated this 28th day of March 2014


Rakhee Sharma
 Of Anand and Anand, Advocates
 Agent for the Patentee

To
 The Controller of Patents,
 The Patent Office,
 Chennai

m
 TC

352

FORM 27
THE PATENT ACT, 1970
(39 OF 1970)
&
THE PATENTS RULES, 2003

No Fee

STATEMENT REGARDING THE WORKING OF THE PATENTED
INVENTION ON COMMERCIAL SCALE IN INDIA
[See section 146(2) and rule 131(1)] (As Amended)]

In the matter of Patent No. 229761 (2653/CHENP/2005) of 15th April, 2004.

We, Novartis AG, a corporation organized and existing under the laws of Switzerland, of 35, Lichtstrasse, CH-4056 Basel, Switzerland.

The patentee(s) or licensee(s) under Patent No. 229761 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2013.

(i) The patented invention:
{} Worked {} Not-worked [Tick () mark the relevant box].

(d) ~~If not worked - reasons for not working and steps being taken for working of the invention:~~

(b) If worked : quantum and value (in Rupees), of the Patented Product:
(i) manufactured in India
(ii) imported from other countries. (give country wise details):

S.No.	Product(s)	Quantum (number of units)	Value (Rs.)
1.	Galvus 500 mg T2x14	2,355,890	915,030,275
2.	Galvus Met 50/500mg 6x10 Tab 50/850mg 6x10 Tab 50/1000mg 6x10 Tab	1,006,262 116,829 423,384	871,822,777 95,367,845 367,309,937
3.	Jaira 50mg 2x14	1,531,626	419,172,976
4.	Jaira M 50/500mg 6x10 Tab 50/850mg 6x10 Tab 50/1000mg 6x10 Tab	538,502 26,779 156,840	345,102,139 17,083,790 100,704,080
5.	Zomelis 50MG T2x14 50/500mg 6x10 Tab 50/1000mg 6x10 Tab	398,021 165,766 54,635	111,921,659 110,087,711 36,139,339
6.	Vysov 50MG T2x14	123,015	33,635,059
7.	Vysov-M 50/500mg 6x10 Tab 50/850mg 6x10 Tab 50/1000mg 6x10 Tab	51,034 21,105 48,928	33,386,910 13,708,821 31,828,771

Imported from Switzerland and Europe
Marketed by : Novartis Healthcare Private Limited


TRUE COPY

(ii) The licenses and sub-licensees granted during the year;
(iii) State whether public requirement has been met partly/adequately/to the fullest extent at reasonable price: Yes
The facts and matters stated above are true to the best of my/our knowledge, information and belief.
Dated this 28 th day of March 2014
<p style="text-align: right;"><i>Rakhee</i> Rakhee Sharma Of Anand and Anand, Advocates Agent for the Patentee</p>
To The Controller of Patents, The Patent Office, Chennai

RV
TC

TRUE COPY

20
354

Form-27

The Patents Act, 1970
(39 of 1970)

STATEMENT REGARDING THE WORKING OF THE PATENTED INVENTION
ON COMMERCIAL SCALE IN INDIA
[See Section 146(2) and rule 131(1)]

In the matter of Patent No. 237273
of 22 December 1999

I/We, NOVARTIS AG

the patentee(s) under Patent No. 237273 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2010.

- (i) The patented invention:
[] worked [✓] not worked (tick relevant box [✓])

If not worked: reason for not working and steps being taken for working of the invention : Nothing in particular

If worked: quantum and value (in Rupees), of the patented product:
Not applicable

Manufactured in India: Not applicable

Imported from other countries. (give country-wise details): Nil

- (ii) the licences and sub-licences granted during the year : Nil
- (iii) state whether public requirement has been met partly / adequately / to the fullest extent at reasonable price: Not applicable

The facts and matters stated above are true to the best of our knowledge, information and belief.

Dated this 28 day of March 2011

NOVARTIS AG
By his/their Agent and Attorney

Dipanjani Som

(Dipanjani Som)
REG. NO. IN/PA/1675
of De Penning & De Penning

The Controller of Patents
The Patent Office at
Chennai

"THIS DOCUMENT IS SUPPLIED
UNDER THE RIGHT TO INFORMATION ACT"

18
PC
COPY

21
355

FORM 27
THE PATENT ACT, 1970
(39 OF 1970)
&
THE PATENTS RULES, 2003

No Fee

STATEMENT REGARDING THE WORKING OF THE PATENTED
INVENTION ON COMMERCIAL SCALE IN INDIA
[See section 146(2) and rule 131(1)] (As Amended)]

In the matter of Patent No. 237273 (638/CHENP/2006) of 22nd December, 1999.

We, Novartis AG, a corporation organized and existing under the laws of Switzerland, of Lichstrasse 35, CH-4056 Basel Switzerland.

The patentee(s) or licensee(s) under Patent No. 237273 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2012.

(i) The patented invention:

{} Worked {} Not-worked [Tick () mark the relevant box].

(a) If not worked: reasons for not working and steps being taken for working of the invention:

(b) If worked: quantum and value (in Rupees), of the Patented Product:

- (i) manufactured in India
- (ii) imported from other countries. (give country wise details)

Product(s)	Quantum (No. of Units)	Value (Rupees)	Imported from:	Marketed by:
Diovan	38,663	32,898,227	Switzerland	Novartis India Limited Sandoz House, 8th floor Shivsagar Estate Dr. Annie Besant Road Worli, Mumbai 400 018
(Co)Diovan	20,292	16,856,109	Europe	

(ii) The licenses and sub-licensees granted during the year: None

(iii) State whether public requirement has been met partly/adequately/to the fullest extent at reasonable price: "YES."

The facts and matters stated above are true to the best of my/our knowledge, information and belief.

Dated this 26th day of March, 2013

Neeth Wilson
Neeth Wilson
Of Anand and Anand, Advocates
Agent for the Patentee

To
The Controller of Patents
The Patent Office, Chennai

356

FORM 27
THE PATENT ACT, 1970
(39 OF 1970)
&
THE PATENTS RULES, 2003
STATEMENT REGARDING THE WORKING OF THE PATENTED
INVENTION ON COMMERCIAL SCALE IN INDIA
[See section 146(2) and rule 131(1)] (As Amended)

In the matter of patent No. 237596 of 16th March, 2006

I/We, Novartis AG, a company organized and existing under the laws of Switzerland, of Lichstrasse 35, CH-4056 Basel, Switzerland the patentee(s) or licensee(s) under Patent No. 237596 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2010.

(i) The patented invention:

Worked Not worked [Tick (✓) mark the relevant box].

(a) If not worked : reasons for not working and steps being taken for working of the invention:

The patented invention is under development or forms part of the potential development portfolio and currently is not worked.

In the Pharma industry there are many new inventions coming under development all the time. An invention needs many years of development before it can be worked e.g. several years of pharmacological/toxicology analysis, several years of clinical trials and/or several years of regulatory administrative processes to approve the product (i.e. with the national Health Authorities).


~~(b) If worked: quantum and value (in Rupees), of the patented product:~~

(ii) The licenses and sub-licensees granted during the year;

(iii) State whether public requirement has been met partly/adequately/to the fullest extent at reasonable price.

The facts and matters stated above are true to the best of my/our knowledge, information and belief.

Dated this 30th day of March, 2011


Vidisha Garg
Of Anand and Anand, Advocates
Agent for the Patentee

To
The Controller of Patents
The Patent Office
Chennai

"THIS DOCUMENT IS SUPPLIED
UNDER THE RIGHT TO INFORMATION ACT"



19
357

FORM 27
THE PATENT ACT, 1970
(39 OF 1970)
&
THE PATENTS RULES, 2003

No Fee

**STATEMENT REGARDING THE WORKING OF THE PATENTED
INVENTION ON COMMERCIAL SCALE IN INDIA**
[See section 146(2) and rule 131(1)] (As Amended)]

In the matter of Patent No. 237596 (923/CHENP/2006) of 17th September, 2004.

We, Novartis AG, a corporation organized and existing under the laws of Switzerland, of Lichstrasse 35, CH-4056 Basel Switzerland.

The patentee(s) or licensee(s) under Patent No. 237596 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2012.

(i) The patented invention:

Worked ~~Not worked~~ [Tick mark the relevant box]:

(a) If not worked + reasons for not working and steps being taken for working of the invention:

(b) If worked : quantum and value (in Rupees), of the Patented Product:

- (i) manufactured in India
- (ii) imported from other countries. (give country wise details)

Product(s)	Quantum (No. of Units)	Value (Rupees)	Imported from:	Marketed by:
Actasta	5,866	73,467,995	Switzerland	Novartis India Limited Sandoz House, 8th floor Shivsagar Estate Dr. Annie Besant Road Worli, Mumbai 400 018
			Europe	

(ii) The licenses and sub-licensees granted during the year: None

(iii) State whether public requirement has been met partly/adequately/to the fullest extent at reasonable price: "YES."

The facts and matters stated above are true to the best of my/our knowledge, information and belief.

Dated this 26th day of March, 2013

Neeti
Neeti Wilson
Of Anand and Anand, Advocates
Agent for the Patentee

To
The Controller of Patents
The Patent Office, Chennai

WC

"THIS DOCUMENT IS SUPPLIED
UNDER THE RIGHT TO INFORMATION ACT"

FORM 27
THE PATENT ACT, 1970
(39 OF 1970)
&
THE PATENTS RULES, 2003

No Fee

**STATEMENT REGARDING THE WORKING OF THE PATENTED
INVENTION ON COMMERCIAL SCALE IN INDIA**
[See section 146(2) and rule 131(1)] (As Amended)]

In the matter of Patent No. 237596 (923/CHENP/2006) of 17th September, 2004.

We, *Novartis AG*, a corporation organized and existing under the laws of Switzerland, of 35, Lichtstrasse, CH-4056 Basel Switzerland.

The patentee(s) or licensee(s) under Patent No. 237596 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2013.

(i) The patented invention:
{} Worked Not-worked [Tick () mark the relevant box].

(a) If not worked : reasons for not working and steps being taken for working of the invention:

(b) If worked : quantum and value (In Rupees), of the Patented Product:
(i) manufactured in India
(ii) Imported from other countries: (give country wise details):


Product: Aclasta
Imported from Switzerland and Europe
Marketed by : Novartis Healthcare Private Limited
Quantum (No. of Units): 4,437
Value: Rupees 57,301,760

(ii) The licenses and sub-licenses granted during the year;

(iii) State whether public requirement has been met partly/adequately/to the fullest extent at reasonable price: Yes

The facts and matters stated above are true to the best of my/our knowledge, information and belief.

Dated this 28th day of March 2014


Rakhee Sharma
Of Anand and Anand, Advocates
Agent for the Patentee

To
The Controller of Patents,
The Patent Office,
Chennai

TRUE COPY

FORM 27
THE PATENT ACT, 1970
(39 OF 1970)
&
THE PATENTS RULES, 2003

**STATEMENT REGARDING THE WORKING OF THE PATENTED
INVENTION ON COMMERCIAL SCALE IN INDIA**
[See section 146(2) and rule 131(1)] (As Amended)]

In the matter of Patent No. 209251 of 15th February, 2001

I/We, **Sugen Inc.**, a corporation organized and existing under the laws of United States of America, of 235 East 42nd Street, New York 10017, USA and **Pharmacia & Upjohn Company**, a corporation organized and existing under the laws of United States of America, of 7000 Portage Road, Kalamazoo, Michigan 49001, USA.

The patentee(s) or licensee(s) under Patent No. 209251 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2012.

(I) The patented invention:
{ } Worked Not worked [tick (✓) mark the relevant box].

~~(a) If not worked + reasons for not working and steps being taken for working of the invention:~~

(b) **If worked** : quantum and value (in Rupees), of the Patented Product:
(i) manufactured in India
(ii) imported from other countries. (give country wise details)

"Indian Patent No. 209251 claims a pharmaceutical product imported into India from Italy, more than 10,907 (exclusive of donation stock) and 6,167 (donation pack) units of which were sold in India in 2012. Sales totaled 262,203,524.17 (In Rupees).

(II) The licenses and sub-licensees granted during the year;

(iii) State whether public requirement has been met, partly adequately/to the fullest extent at reasonable price.

The facts and matters stated above are true to the best of my/our knowledge, information and belief.

Dated this 19th day of February 2013

GOVT. OF INDIA PATENT OFFICE
No. _____
28 MAR 2013
NEEL WILSON
Of Anand and Anand, Advocates
Agent for the Patentee

To
The Controller of Patents,
The Patent Office, Delhi

TRUE COPY

FORM 27

THE PATENT ACT, 1970
(39 OF 1970) &
&
THE PATENTS RULES, 2003
(As Amended)

STATEMENT REGARDING THE WORKING OF THE PATENTED
INVENTION ON COMMERCIAL SCALE IN INDIA

[See section 146(2) and rule 131(1)]

In the matter of patent No. 211539 of 26.08.1999.

I/We, Pharmacia & Upjohn, the patentee(s) under Patent No. 211539 hereby furnish the following statement regarding the working of the patented invention referred to above on a commercial scale in India for the year 2010.

- (i) The patented invention:*
{ } Worked { } Not worked [Tick (✓) mark the relevant box]

*Indian Patent No. 211539 claims a pharmaceutical formulation imported from Italy and more than 25,000 units of the product were sold in India in 2010.

The facts and matters stated above are true to the best of my/our knowledge, information and belief.

Dated this 30th day of March, 2011



Archana Shanker
Of Anand and Anand, Advocates
Agent for the Patentee

To
The Controller of Patents
The Patent Office
CHENNAI

TRUE COPY

"THIS DOCUMENT IS SUPPLIED
UNDER THE RIGHT TO INFORMATION ACT"